Search
Patient-reported outcome measures (PROMs) are recommended for capturing meaningful outcomes in clinical trials. The use of PROMs for children with acute lower respiratory infections (ALRIs) has not been systematically reported. We aimed to identify and characterise patient-reported outcomes and PROMs used in paediatric ALRI studies and summarise their measurement properties.
Atopic diseases are the most common chronic conditions of childhood. The apparent rise in food anaphylaxis in young children over the past three decades is of particular concern, owing to the lack of proven prevention strategies other than the timely introduction of peanut and egg.
Atopic diseases are the most common chronic conditions of childhood. The apparent rise in food anaphylaxis in young children over the past three decades is of particular concern, owing to the lack of proven prevention strategies other than the timely introduction of peanut and egg.
The burden of IgE-mediated food allergy in Australian born children is reported to be among the highest globally. This illness shares risk factors and frequently coexists with asthma, one of the most common noncommunicable diseases of childhood.
To determine the proportion of first status epilepticus cases that are vaccine-proximate and compare clinical outcomes to non-vaccine-proximate cases.
Christopher Peter Peter Tom Blyth Jacoby Richmond Snelling MBBS (Hons) DCH FRACP FRCPA PhD BA (Hons) MSc MBBS MRCP(UK) FRACP BMBS DTMH GDipClinEpid
In the absence of an established gold standard, an understanding of the testing cycle from individual exposure to test outcome report is required to guide the correct interpretation of SARS-CoV-2 reverse transcriptase real-time polymerase chain reaction (RT-PCR) results and optimise the testing processes.
We have demonstrated the potential use of Bayesian Networks in improving antibiotic selection for children with osteomyelitis
Australian infants who received whole-cell pertussis vaccines were less likely to be diagnosed with food allergy in childhood
No new safety concerns were identified for live attenuated herpes zoster vaccine in this study based on a novel, Australian primary care data source